RT Journal Article
SR Electronic
T1 The impact of major depressive disorder on glycaemic control in type 2 diabetes: a longitudinal cohort study using UK Biobank primary care records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.13.22269229
DO 10.1101/2022.01.13.22269229
A1 Gillett, Alexandra C
A1 Hagenaars, Saskia P
A1 Handley, Dale
A1 Casanova, Francesco
A1 Young, Katherine G
A1 Green, Harry
A1 Lewis, Cathryn M
A1 Tyrrell, Jess
YR 2024
UL http://medrxiv.org/content/early/2024/01/05/2022.01.13.22269229.abstract
AB Background This study evaluates longitudinal associations between glycaemic control (mean and within-patient variability of glycated haemaglobin (HbA1c) levels) in individuals with type 2 diabetes (T2D) and major depressive disorder (MDD), focusing on the timings of these diagnoses.Methods In UK Biobank, T2D was defined using self-report and linked health outcome data, then validated using polygenic scores. Repeated HbA1c measurements (mmol/mol) over the 10 years following T2D diagnosis were outcomes in mixed effects models, with T2D disease duration included using restricted cubic splines. Four MDD exposures were considered: MDD diagnosis prior to T2D diagnosis (pre-T2D MDD), time between pre-T2D MDD diagnosis and T2D, new MDD diagnosis during follow-up (post-T2D MDD) and time since post-T2D MDD diagnosis. Models with and without covariate adjustment were considered.Results T2D diagnostic criteria were robustly associated with T2D polygenic scores. In 11,837 T2D cases (6.9 year median follow-up), pre-T2D MDD was associated with a 0.92 increase in HbA1c (95% CI: [0.00, 1.84]), but earlier pre-T2D MDD diagnosis correlated with lower HbA1c. These pre-T2D MDD effects became non-significant after covariate adjustment. Post-T2D MDD individuals demonstrated increasing HbA1c with years since MDD diagnosis (/3 = 0.51, 95% CI: [0.17, 0.86]). Retrospectively, looking across all follow-up, within-patient variability in HbA1c was 1.16 (95% CI: 1.13-1.19) times higher in post-T2D MDD.Conclusions The timing of MDD diagnosis is important for understanding glycaemic control in T2D. Poorer control was observed in MDD diagnosed post-T2D, highlighting the importance of depression screening in T2D, and closer monitoring for individuals who develop MDD after T2D.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis paper represents independent research part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The authors acknowledge use of the research computing facility at King's College London, CREATE. This research as supported by the Medical Research Council (MR/S0151132; MR/N015746). JT and FC are supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK [SBF004\1079]. KGY is supported by Research England's Expanding Excellence in England (E3) fund. HG is funded by an E3 Independent Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the NHS North West Research Ethics Committee (REC reference 11/NW/0382). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from UK Biobank subject to standard access procedures (www.ukbiobank.ac.uk). http://www.ukbiobank.com HbA1cGlycated haemaglobinT2DType 2 diabetesMDDMajor depressive disorderUKBUK BiobankGPGeneral practionerPGSPolygenic scoreBMIBody mass indexSBPSystolic blood pressureDBPDiastolic blood pressureMEMMixed effects modelCAR1Continuous-time autoregressive 1LRTLikelihood ratio testMIMultiple imputationCIConfidence intervalIQRInterquartile rangeHESHospital episode statistics